Monoclonal antibody inhibition of PAR2 reduces phenotype severity and pain in murine inflammatory bowel disease.
Saved in:
| Title: | Monoclonal antibody inhibition of PAR2 reduces phenotype severity and pain in murine inflammatory bowel disease. |
|---|---|
| Authors: | Ritoux A; Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom., Grundy LJ; Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom., Manjappa P; Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Paine LW; Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom., Neisen J; Translational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Linley JE; Neuroscience, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Smith ESJ; Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom. |
| Source: | Pain reports [Pain Rep] 2026 Apr 20; Vol. 11 (3), pp. e1446. Date of Electronic Publication: 2026 Apr 20 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Wolters Kluwer Country of Publication: United States NLM ID: 101683899 Publication Model: eCollection Cited Medium: Internet ISSN: 2471-2531 (Electronic) Linking ISSN: 24712531 NLM ISO Abbreviation: Pain Rep Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2471-2531 |
|---|---|
| DOI: | 10.1097/PR9.0000000000001446 |
